BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, April 23, 2026
Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
Immuno-oncology RSS Feed RSS

Targeted cancer cell
Immuno-oncology

First CAR T against head and neck cancer associated with Fanconi anemia

Oct. 7, 2025
No Comments
Individuals with the inherited disorder Fanconi anemia cannot properly repair damage to their DNA, increasing risk of cancers such as head and neck squamous cell carcinoma (HNSCC).
Read More
Cancer diagnostic illustration
Cancer

New AI model can assign certainty, or uncertainty, to predictions

Oct. 7, 2025
By Marian (YoonJee) Chu
No Comments
A team of U.S. and South Korean researchers have developed an AI model called MSI-SEER that can not only predict microsatellite instability-high (MSI-H) tumors based on tissue slides, but also flag “what it does not know.” “Have you ever asked ChatGPT anything, and the response was, ‘I don’t know?’” Cheong Jae-ho asked during an interview with BioWorld. “Probably not, and that is the problem with AI now.”
Read More
Immuno-oncology

Aligos Therapeutics reports new PD-1/PD-L1 interaction inhibitors

Oct. 6, 2025
Work at Aligos Therapeutics Inc. has led to the discovery of new programmed cell death 1 (PDCD1; PD-1; CD279)/PD-1 ligand 1 (PD-L1; CD274) interaction inhibitors reported to be useful for the treatment of hepatocellular carcinoma and hepatitis B.
Read More
Immuno-oncology

Targeting PUS1 activates antiviral immunity, sensitizes liver tumors to anti-PD-1 therapy

Oct. 6, 2025
No Comments
In an isomerization reaction, uridine is modified to pseudouridine, the most abundant RNA modification which presents an extra hydrogen bond donor, altering the RNA structure and providing unique chemical properties.
Read More
Blue dollar sign on white background
Immuno-oncology

Cartography Biosciences' series B financing will advance lead program

Oct. 3, 2025
No Comments
Cartography Biosciences Inc. has closed a $67 million series B financing to support its pipeline of T-cell engaging bispecific and multispecific antibody therapeutics that target novel and highly specific tumor antigens.
Read More
Colorectal cancer 3D illustration
Immuno-oncology

Bispecific antibody against CD40 and CEACAM5 to fight colorectal carcinoma

Oct. 2, 2025
No Comments
Researchers at Alligator Bioscience AB and Lund University have developed a bispecific therapeutic antibody, ATOR-4066, that simultaneously targets the immune cell receptor CD40 and the tumor antigen CEACAM5.
Read More
3D illustration of ovarian cancer cells
Immuno-oncology

PB-vcMMAE-5 shows promise for ovarian cancer

Oct. 1, 2025
No Comments
Ovarian cancer remains unresponsive to immune checkpoint inhibitors due to its ability to suppress cytotoxicity from immune cells that are infiltrating the tumor, where the O-glycosylation pathway may be disrupted. Precision Biologics Inc. is developing PB-vcMMAE-5, an antibody-drug conjugate composed of the monoclonal antibody PB-223, which targets tumor-specific truncated core-2 O-glycans, conjugated to microtubule inhibitor MMAE and with a drug-to-antibody ratio of 3.92.
Read More
3d rendering of bispecific antibodies
Immuno-oncology

Debiopharm licenses Sunrock’s bispecific HER3/HER2 antibody

Oct. 1, 2025
No Comments
Debiopharm SA has exercised its option to license Sunrock Biopharma SL’s SRB-21, a bispecific HER3/HER2 antibody.
Read More
3D molecular view of liquid-liquid phase separation
Immune

Condensates and innate immunity in Clarivate’s Citation Laureates

Sep. 30, 2025
By Mar de Miguel
No Comments
Clarivate plc has unveiled the 2025 Citation Laureates. Widely considered a predictor of the Nobel Prizes, this recognition has highlighted the discovery of biomolecular condensates in chemistry and the innate immunity signaling pathway in physiology or medicine, as well as the identification of leukemia stem cells and ghrelin, the so-called hunger hormone.
Read More
Computer visualization of a CAR T cell attacking a cancer cell.
Cancer

CRISPR boosts CAR T cells for leukemia and myeloma

Sep. 30, 2025
By Mar de Miguel
No Comments
Two independent studies applied CRISPR-based genetic editing – one to treat leukemia and the other to target myeloma – to overcome the challenges faced by CAR T cells, such as exhaustion, impaired activation and fratricide, a phenomenon in which they attack each other.
Read More
Previous 1 2 … 21 22 23 24 25 26 27 28 29 … 1001 1002 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 22, 2026.
  • Man holding raised arm with illustrated overlay of nerves

    Biohaven reports details on discovery of BHV-2100

    BioWorld Science
    Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
  • Elderly woman holding illustration of brain with missing puzzle piece

    Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’

    BioWorld
    The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
  • New GABA(B) receptor PAMs revealed in Addex Pharma patents

    BioWorld Science
    Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
  • MMP inhibitors divulged in Accure Therapeutics patent

    BioWorld Science
    Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing